As cash-rich molecular diagnostics companies scale volume and expand menu breadth, there could be an "acqui-hire" shockwave.
These growing companies likely will continue vertically integrating in front (sample prep) and behind (informatics) to gain . . . (1/4)
These growing companies likely will continue vertically integrating in front (sample prep) and behind (informatics) to gain . . . (1/4)
. . . operating efficiencies on the move up. Or, there could be a weak link in the existing R&D pipeline that needs mending all-of-a-sudden. For example, that extracting bite-size #epigenetic signal from blood would be central to earlier #cancer detection . . . (2/4)
. . . maybe wasn't as obvious five years ago. There seems to be a ton of awesome IP/university spinouts that've gone on to become private companies and/or patents. Along with this, a fleet of brilliant scientists/impassioned people who . . . (3/4)
. . . may have more opportunities to join ranks with like-minded researchers in R&D divisions of high-growth MolDx firms. (4/4)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
